Clinical trial
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor…
NCT00265798 · National Cancer Institute (NCI), NIH · Active, not recruiting
Key facts
| NCT number | NCT00265798 |
|---|---|
| Title | Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate |
| Official title | A Phase 2 Study of BAY 43-9006 for Imatinib- and Sunitinib Resistant Gastrointestinal Stromal Tumor |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug |
| Interventions | Sorafenib Tosylate |
| Enrollment | 38 |
| Start date | Sep 14, 2005 |
| Primary completion | Feb 11, 2010 |
| Completion | Mar 19, 2026 |
| First posted | Dec 15, 2005 |
| Last update posted | Aug 20, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: